Published in Mol Cell Proteomics on December 08, 2011
Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance. Mol Cell Proteomics (2012) 1.72
Molecular insights on context-specific role of profilin-1 in cell migration. Cell Adh Migr (2012) 1.07
Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clin Transl Med (2014) 1.05
Profilin-1 downregulation has contrasting effects on early vs late steps of breast cancer metastasis. Oncogene (2013) 0.99
High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment. World J Urol (2012) 0.97
Subcellular localization and Ser-137 phosphorylation regulate tumor-suppressive activity of profilin-1. J Biol Chem (2015) 0.89
Does phosphorylation of cofilin affect the progression of human bladder cancer? BMC Cancer (2013) 0.87
Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers. Nat Rev Urol (2013) 0.87
Profilin-1 suppresses tumorigenicity in pancreatic cancer through regulation of the SIRT3-HIF1α axis. Mol Cancer (2014) 0.85
Developing proteomic biomarkers for bladder cancer: towards clinical application. Nat Rev Urol (2015) 0.84
Silencing profilin-1 inhibits gastric cancer progression via integrin β1/focal adhesion kinase pathway modulation. World J Gastroenterol (2015) 0.84
Profilin-1 versus profilin-2: two faces of the same coin? Breast Cancer Res (2013) 0.83
Protein interactome of muscle invasive bladder cancer. PLoS One (2015) 0.82
Bladder cancer: a simple model becomes complex. Curr Genomics (2012) 0.81
New selective peptidyl di(chlorophenyl) phosphonate esters for visualizing and blocking neutrophil proteinase 3 in human diseases. J Biol Chem (2014) 0.80
Profilin 1 is essential for retention and metabolism of mouse hematopoietic stem cells in bone marrow. Blood (2014) 0.80
Elevated urinary level of vitamin D-binding protein as a novel biomarker for diabetic nephropathy. Exp Ther Med (2013) 0.80
Proteotranscriptomic Analysis Reveals Stage Specific Changes in the Molecular Landscape of Clear-Cell Renal Cell Carcinoma. PLoS One (2016) 0.80
S137 phosphorylation of profilin 1 is an important signaling event in breast cancer progression. PLoS One (2014) 0.79
Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a Label-Free LC-MS/MS Approach. PLoS One (2015) 0.78
Contextualised urinary biomarker analysis facilitates diagnosis of paediatric obstructive sleep apnoea. Sleep Med (2014) 0.77
Label-free quantitative urinary proteomics identifies the arginase pathway as a new player in congenital obstructive nephropathy. Mol Cell Proteomics (2014) 0.76
Profilin1 biology and its mutation, actin(g) in disease. Cell Mol Life Sci (2016) 0.76
Ten Years of Proteomics in Bladder Cancer: Progress and Future Directions. Bladder Cancer (2017) 0.75
Silencing of Profilin-1 suppresses cell adhesion and tumor growth via predicted alterations in integrin and Ca2+ signaling in T24M-based bladder cancer models. Oncotarget (2016) 0.75
Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of -omics findings. Sci Rep (2016) 0.75
Analytical Performance of ELISA Assays in Urine: One More Bottleneck towards Biomarker Validation and Clinical Implementation. PLoS One (2016) 0.75
A Loss of Profilin-1 in Late Stage Oral Squamous Cell Carcinoma. J Oral Pathol Med (2016) 0.75
Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis (2004) 6.97
Metal chelate affinity chromatography, a new approach to protein fractionation. Nature (1975) 5.83
Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics (2005) 2.66
Focus on bladder cancer. Cancer Cell (2004) 2.59
The role of profilin complexes in cell motility and other cellular processes. Trends Cell Biol (2004) 2.58
In mouse brain profilin I and profilin II associate with regulators of the endocytic pathway and actin assembly. EMBO J (1998) 2.53
The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl (2008) 2.48
Urinary markers in bladder cancer. Eur Urol (2007) 1.95
Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol (2001) 1.88
The moonlighting enzyme CD13: old and new functions to target. Trends Mol Med (2008) 1.70
Suppression of tumorigenicity in breast cancer cells by the microfilament protein profilin 1. J Exp Med (2000) 1.61
Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin Cancer Res (2000) 1.60
Silver staining of proteins in polyacrylamide gels. Nat Protoc (2006) 1.58
Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res (2008) 1.54
Proteomics of MUC1-containing lipid rafts from plasma membranes and exosomes of human breast carcinoma cells MCF-7. Proteomics (2009) 1.49
Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem (2005) 1.46
Secretome proteomics for discovery of cancer biomarkers. J Proteomics (2010) 1.44
Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells. Stem Cells Dev (2007) 1.36
Current and prospective applications of metal ion-protein binding. J Chromatogr A (2003) 1.34
Loss of profilin-1 expression enhances breast cancer cell motility by Ena/VASP proteins. J Cell Physiol (2009) 1.30
The profile of profilins. Rev Physiol Biochem Pharmacol (2007) 1.29
Profilin 1 obtained by proteomic analysis in all-trans retinoic acid-treated hepatocarcinoma cell lines is involved in inhibition of cell proliferation and migration. Proteomics (2006) 1.27
Bladder cancer. Curr Opin Oncol (2009) 1.26
Perspectives of immobilized-metal affinity chromatography. J Biochem Biophys Methods (2001) 1.26
Immobilized-metal affinity chromatography (IMAC): a review. Methods Enzymol (2009) 1.26
Tumor suppressor activity of profilin requires a functional actin binding site. Mol Biol Cell (2004) 1.23
Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis. Electrophoresis (2010) 1.19
Inhibition of intrinsic proteolytic activities moderates preanalytical variability and instability of human plasma. J Proteome Res (2007) 1.17
Overexpression of profilin reduces the migration of invasive breast cancer cells. Cell Motil Cytoskeleton (2004) 1.16
Transaldolase: from biochemistry to human disease. Int J Biochem Cell Biol (2009) 1.14
Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol (2010) 1.12
Toward a better analysis of secreted proteins: the example of the myeloid cells secretome. Proteomics (2007) 1.12
Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin Appl (2010) 1.12
Mass spectrometric proteomics profiles of in vivo tumor secretomes: capillary ultrafiltration sampling of regressive tumor masses. Proteomics (2006) 1.11
The cancer cell secretome: a good source for discovering biomarkers? J Proteomics (2010) 1.09
UTRN on chromosome 6q24 is mutated in multiple tumors. Oncogene (2007) 1.04
Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel electrophoresis (2D-DIGE) approach. J Proteome Res (2007) 1.03
Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis. Clin Chem (2008) 1.02
Urine profiling by SELDI-TOF/MS: monitoring of the critical steps in sample collection, handling and analysis. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 1.01
Neutrophil serine proteases: mediators of innate immune responses. Curr Opin Hematol (2011) 1.00
Searching for serum tumor markers for colorectal cancer using a 2-D DIGE approach. Electrophoresis (2009) 1.00
Molecular markers in bladder cancer: a critical appraisal. Urol Oncol (2006) 0.99
Immunohistochemical biomarkers for bladder cancer prognosis. Int J Urol (2011) 0.96
Profilin-1 overexpression inhibits proliferation of MDA-MB-231 breast cancer cells partly through p27kip1 upregulation. J Cell Physiol (2010) 0.94
Profilin-1 overexpression restores adherens junctions in MDA-MB-231 breast cancer cells in R-cadherin-dependent manner. Cell Motil Cytoskeleton (2009) 0.94
Are protease inhibitors required for gel-based proteomics of kidney and urine? J Proteome Res (2009) 0.94
Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma. Ann Diagn Pathol (2011) 0.93
Novel aminopeptidase N (APN/CD13) inhibitor 24F can suppress invasion of hepatocellular carcinoma cells as well as angiogenesis. Biosci Trends (2010) 0.90
Biomarkers for prognosis and treatment selection in advanced bladder cancer patients. Curr Opin Urol (2011) 0.90
Matrix metalloproteinases (MMPs) in bladder cancer: the induction of MMP9 by epidermal growth factor and its detection in urine. BJU Int (2003) 0.89
Analysis of secreted proteins for the study of bladder cancer cell aggressiveness. J Proteome Res (2010) 0.89
Secretome-based proteomics reveals sulindac-modulated proteins released from colon cancer cells. Proteomics Clin Appl (2009) 0.85
Apoptosis-induced proteinase 3 membrane expression is independent from degranulation. J Leukoc Biol (2003) 0.84
Serum and tissue profiling in bladder cancer combining protein and tissue arrays. J Proteome Res (2010) 0.84
Chromosomal and proteome analysis of a new T24-based cell line model for aggressive bladder cancer. Proteomics (2009) 0.83
Comparison of three methods for fractionation and enrichment of low molecular weight proteins for SELDI-TOF-MS differential analysis. Talanta (2010) 0.82
Multidimensional protein fractionation of blood proteins coupled to data-independent nanoLC-MS/MS analysis. J Proteomics (2009) 0.81
Molecular and immunohistologic analyses cannot reliably solve diagnostic variation of flat intraepithelial lesions of the urinary bladder. Am J Clin Pathol (2010) 0.81
Assessment of fibrin-fibrinogen degradation products (Accu-Dx) test in bladder cancer patients. Eur Urol (2001) 0.80
Identification of free phosphopeptides in different biological fluids by a mass spectrometry approach. Anal Bioanal Chem (2008) 0.78
Phospho-proteomic approach to identify new targets of leucine deprivation in muscle cells. Anal Biochem (2008) 0.78
Neutrophil granule proteins as targets of leukemia-specific immune responses. Curr Opin Hematol (2006) 0.76
Design, synthesis and primary activity assay of bi- or tri-peptide analogues with the scaffold l-arginine as amino-peptidase N/CD13 inhibitors. Bioorg Med Chem (2009) 0.76
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
A DNA methylation fingerprint of 1628 human samples. Genome Res (2011) 2.16
RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. J Clin Invest (2012) 1.92
Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin. Eur Urol (2008) 1.65
Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med (2010) 1.59
Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours. Eur Urol (2011) 1.55
Analysis of the urine proteome via a combination of multi-dimensional approaches. Proteomics (2012) 1.49
Proteome-based systems biology analysis of the diabetic mouse aorta reveals major changes in fatty acid biosynthesis as potential hallmark in diabetes mellitus-associated vascular disease. Circ Cardiovasc Genet (2014) 1.44
Secretome proteomics for discovery of cancer biomarkers. J Proteomics (2010) 1.44
Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J Clin Invest (2010) 1.39
Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol (2011) 1.39
Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells. Stem Cells Dev (2007) 1.36
Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience. Clin Biochem (2012) 1.18
Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC Bioinformatics (2010) 1.16
Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer. Cancer Res (2010) 1.14
Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int (2006) 1.12
Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer (2004) 1.12
Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol (2010) 1.12
Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin Appl (2010) 1.12
Molecular profiling of tumor progression in head and neck cancer. Arch Otolaryngol Head Neck Surg (2005) 1.10
Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol (2006) 1.06
Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. J Proteome Res (2008) 1.05
Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol (2012) 1.04
Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am J Pathol (2012) 1.03
Characterization of the human urine proteome by preparative electrophoresis in combination with 2-DE. Proteomics (2006) 1.03
Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin Cancer Res (2009) 1.02
Implementation of proteomic biomarkers: making it work. Eur J Clin Invest (2012) 1.00
Diagnosis of Ovarian Cancer Using Decision Tree Classification of Mass Spectral Data. J Biomed Biotechnol (2003) 1.00
A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition. Cancer Res (2009) 0.99
Overexpression of alpha-defensin is associated with bladder cancer invasiveness. Urol Oncol (2006) 0.98
Loss of SPARC in bladder cancer enhances carcinogenesis and progression. J Clin Invest (2013) 0.97
Sox2 suppression by miR-21 governs human mesenchymal stem cell properties. Stem Cells Transl Med (2013) 0.97
Downregulation and prognostic performance of microRNA 224 expression in prostate cancer. Clin Chem (2012) 0.96
Stem cells: insights into the secretome. Biochim Biophys Acta (2013) 0.95
Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization. Clin Cancer Res (2013) 0.94
OCT4 spliced variant OCT4B1 is expressed in human colorectal cancer. Mol Carcinog (2011) 0.93
In vitro and in vivo properties of distinct populations of amniotic fluid mesenchymal progenitor cells. J Cell Mol Med (2011) 0.93
Characterization and comparative performance of lentiviral vector preparations concentrated by either one-step ultrafiltration or ultracentrifugation. Virus Res (2013) 0.92
Sample preparation and bioinformatics in MALDI profiling of urinary proteins. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.92
Proteasix: a tool for automated and large-scale prediction of proteases involved in naturally occurring peptide generation. Proteomics (2013) 0.91
KiSS-1 methylation and protein expression patterns contribute to diagnostic and prognostic assessments in tissue specimens for colorectal cancer. Tumour Biol (2012) 0.91
A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI. BMC Syst Biol (2013) 0.90
Biomarkers for bladder cancer aggressiveness. Curr Opin Urol (2012) 0.90
Establishment of a European Network for Urine and Kidney Proteomics. J Proteomics (2008) 0.89
Analysis of secreted proteins for the study of bladder cancer cell aggressiveness. J Proteome Res (2010) 0.89
Clinical proteomics in obstetrics and neonatology. Expert Rev Proteomics (2014) 0.88
Human amniotic fluid stem cells as an attractive tool for clinical applications. Curr Stem Cell Res Ther (2013) 0.88
Androgens and bladder outlet obstruction: a correlation with pressure-flow variables in a preliminary study. BJU Int (2008) 0.86
A novel function for the haemopoietic supportive murine bone marrow MS-5 mesenchymal stromal cell line in promoting human vasculogenesis and angiogenesis. Br J Haematol (2012) 0.86
Human amniotic fluid-derived mesenchymal stem cells as therapeutic vehicles: a novel approach for the treatment of bladder cancer. Stem Cells Dev (2011) 0.86
Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases. Expert Rev Proteomics (2014) 0.85
Cyclin D3 gene amplification in bladder carcinoma in situ. Virchows Arch (2010) 0.85
Evaluation of the Zucker diabetic fatty (ZDF) rat as a model for human disease based on urinary peptidomic profiles. PLoS One (2012) 0.85
Marked defects in the expression and glycosylation of alpha2-HS glycoprotein/fetuin-A in plasma from neonates with intrauterine growth restriction: proteomics screening and potential clinical implications. Mol Cell Proteomics (2007) 0.84
Serum and tissue profiling in bladder cancer combining protein and tissue arrays. J Proteome Res (2010) 0.84
Aseptic meningitis with urinary retention: a case report. Case Rep Med (2011) 0.84
Systems biology: opening new avenues in clinical research. Nephrol Dial Transplant (2010) 0.84
Chromosomal and proteome analysis of a new T24-based cell line model for aggressive bladder cancer. Proteomics (2009) 0.83
Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma. BJU Int (2008) 0.83
CE-MS-based proteomics in biomarker discovery and clinical application. Proteomics Clin Appl (2015) 0.83
Epidemiologic design and analysis for proteomic studies: a primer on -omic technologies. Am J Epidemiol (2015) 0.83
Drug resistance in natural isolates of Leishmania donovani s.l. promastigotes is dependent of Pgp170 expression. PLoS One (2013) 0.83
TiO2-ZrO2 affinity chromatography polymeric microchip for phosphopeptide enrichment and separation. Lab Chip (2011) 0.82
The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma. BMC Cancer (2014) 0.82
Advances in urinary proteome analysis and applications in systems biology. Bioanalysis (2014) 0.82
Pain during transrectal ultrasonography guided prostate biopsy: a randomized prospective trial comparing periprostatic infiltration with lidocaine with the intrarectal instillation of lidocaine-prilocain cream. World J Urol (2003) 0.81
Subtle proteome differences identified between post-dormant vegetative and floral peach buds. J Proteomics (2011) 0.81
Stem cells as potential targeted therapy for inflammatory bowel disease. Inflamm Bowel Dis (2014) 0.81
Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: Focus on Bladder Cancer. Proteomics Clin Appl (2013) 0.81
Antiviral Stratagems Against HIV-1 Using RNA Interference (RNAi) Technology. Evol Bioinform Online (2013) 0.81
The hematopoietic chemokine CXCL12 promotes integration of human endothelial colony forming cell-derived cells into immature vessel networks. Stem Cells Dev (2014) 0.80
Transitional cell carcinoma of ureteral stump after radical nephrectomy in a patient with a history of bladder carcinoma. Int Urol Nephrol (2004) 0.80
Urine sample preparation and protein profiling by two-dimensional electrophoresis and matrix-assisted laser desorption ionization time of flight mass spectroscopy. Methods Mol Biol (2008) 0.80
IMAC fractionation in combination with LC-MS reveals H2B and NIF-1 peptides as potential bladder cancer biomarkers. J Proteome Res (2013) 0.80
Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Cancer Sci (2009) 0.80
Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer. BJU Int (2012) 0.79